SelectScience
Join Free
Accelerating Science
NewsLife Sciences

First FDA Approved CDx for RET fusion-positive metastatic non-small cell lung cancer (NSCLC)

Thermo Fisher Scientific

This makes the Oncomine Dx Target Test the first NGS-based companion diagnostic for RET fusion-positive NSCLC and expands the test’s utility

8 Sept 2020
Sophie Ball
Publishing / Media

Product news

The FDA has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to identify RET fusion-positive metastatic non-small cell lung cancer (NSCLC) patients who are candidates for GAVRETO™ (pralsetinib), a recently approved targeted therapy developed by Blueprint Medicines. This makes the Oncomine Dx Target Test the first NGS-based companion diagnostic for RET fusion-positive NSCLC and expands the test’s utility.

GAVRETO is a potent and selective once-daily oral therapy designed to target RET fusions and mutations. RET fusions are believed to be key disease drivers in about 1-2 percent of patients with NSCLC, which accounts for 85 percent of all lung cancers in the United States. New data show that NSCLC mortality has been declining in recent years, suggesting that advances in treatment, including targeted therapies, may be contributing to improved survival rates.

The Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC. In 2017, the FDA approved it as a CDx to identify patients who may be eligible for specific targeted therapies. The Oncomine Dx Target Test is currently approved and reimbursed by government and commercial insurers in the U.S., Europe, Japan, South Korea and Israel, covering more than 550 million lives globally.

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Thermo Fisher ScientificCompany website

Tags

BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Next Generation SequencingNext-generation sequencing (NGS), also known as whole-genome sequencing, high-throughput sequencing and massive parallel sequencing, produces and analyses thousands to millions of nucleotide sequences at once. Sequencing systems operate via varying technologies depending on the manufacturer, including sequencing by synthesis, ligation, pyrosequencing, ion semiconductor and single-molecule real-time sequencing. For NGS, library preparation is paramount to successful sequencing. In this section, explore a range of library preparation kits, from targeted, amplicon-based or hybridization-based kits including epigenomic, transcriptomic and genomic workflows to fragmentation kits. Find the best next-generation sequencing products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Cancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.

Related articles

First FDA Approved CDx for RET fusion-positive metastatic non-small cell lung cancer (NSCLC)